|
1) Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996; 335: 91-7
|
|
|
|
2) Child JA, Morgan GJ, Davies S, et al. High dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-83
|
|
|
|
|
|
3) Has autologous stem cell transplantation (ASCT) become the gold standard treatment in multiple myeloma？ IX th International Myeloma Workshop. S55-61
|
|
|
|
|
|
4) Perea G, Sureda A, Martino R, et al. Predictive factors for a successful mobilization of peripheral blood CD34＋ cells in multiple myeloma. Ann Hematol. 2001; 80: 592-7
|
|
|
|
|
|
5) Jantunen E, Putkonem M, Nousiannen T, et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant. 2003; 31: 347-51
|
|
|
|
|
|
6) Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multple myeloma. Cancer. 2004; 100: 2607-12
|
|
|
|
|
|
7) Donato ML, Aleman A, Champlin RE, et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 2004; 45: 755-9
|
|
|
|
|
|
8) Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349: 2495-502
|
|
|
|
|
|
9) Fermand JP, Alberti C, Marolleau JP. Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC; results of a two by two designed randomized trial in 230 young patients with multiple myeloma (abstract). Hematol J. 2003; 4: S59
|
|
|
|
|
|
10) Sonneveld P, van der Holt B, Segeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized phase III HOVON 24 study. Haematoll Hematol J. 2005; 90: 37 PL 8. 01
|
|
|
|
|
|
11) Doldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 Trial. Haematologica. 2005; 90: 38 PL 8. 02
|
|
|
|
|
|
12) Goldshmidt H, Sonneved P, Crenner FW, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003; 82: 654-9
|
|
|
|
|
|
13) Bjorkstrand B, Svensson H, Goldshmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001; 27: 511-5
|
|
|
|
|
|
14) Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-30
|
|
|
|
|
|
15) Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroup Francophone du Myelome. Haematol Hematol J. 2005; 90: 19 PL 4. 01
|
|
|
|
|
|
16) Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med. 1991; 325: 1267-73
|
|
|
|
|
|
17) Bjorkstrand B, Ljumgman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1996; 88: 4711-8
|
|
|
|
|
|
18) Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centers. Br J Haematol. 2001; 113: 209-16
|
|
|
|
|
|
19) Slavin S, Nagler A, Napararstek T, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood. 1998; 91: 756-63
|
|
|
|
|
|
20) Mehta J, Singhal S. Graft-versus-myeloma. Bone marrow Transplant. 1998; 22: 853-43
|
|
|
|
|
|
21) Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002; 30: 367-73
|
|
|
|
|
|
22) Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002; 20: 1295-303
|
|
|
|
|
|
23) Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003; 31: 73-80
|
|
|
|
|
|
24) Gerull S, Hegenbart U, Goener M, et al. Non-myeloabrative allogeneic transplantation in patients with relapsed or refractory multiple myeloma. Blood. 2004; 104: 2759 (ASH Annual Meeting Abstracts)
|
|
|
|
|
|
25) Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002; 100: 755-60
|
|
|
|
|
|
26) Maloney DG, Molina AJ, Sahebie F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003; 102: 3447-54
|
|
|
|
|
|
27) Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007; 356: 1110-20
|
|
|
|
|
|
28) Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99- 03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006; 107: 3474-80
|
|
|
|
|
|
29) Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003; 31: 73-80
|
|
|
|
|
|
30) Mateos MV, Hemandez JM, Hemandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: of a multicenter phase 1/2 study. Blood. 2006; 108: 2165-72
|
|
|
|
|
|
31) Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007; 21: 164-8
|
|
|
|
|
|
32) Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007; 138: 176-85
|
|
|
|
|